Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06932081 · ClinicalTrials.gov registry record
Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry
A clinical trial of Congenital Heart Disease and Single-ventricle, sponsored by Leiden University Medical Center.
- Recruiting
- Registry status
- 400
- Enrollment target
- 11
- Study locations
NCT06932081: Recruiting study of Congenital Heart Disease and Single-ventricle, sponsored by Leiden University Medical Center.
NCT06932081 is a study of Congenital Heart Disease and Single-ventricle that is actively recruiting participants, run by Leiden University Medical Center. The registered enrollment target is 400 participants, below the 468-participant average among 63 other Congenital Heart Disease trials with a reported enrollment target (15% lower). The trial reports 11 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06932081, a study of Congenital Heart Disease and Single-ventricle, is actively recruiting participants, sponsored by Leiden University Medical Center.
- RECRUITING
- Registry status
- 400 participants
- Enrollment target
- 11
- Study locations
Study Summary
This real-world, international registry aims to evaluate the current experience with sodium-glucose cotransporter 2 inhibitors (SGLT2i) in adult congenital heart disease (ACHD) patients by investigating the prescription patterns, safety, tolerability, and potential beneficial effects on heart failure-related outcomes.
Primary Outcome
The primary outcome of this registry is an overview of the prescription patterns of SGLT2i in the ACHD population.
Conditions Studied
Interventions
- DRUG SGLT2 inhibitors
Study Locations (11)
Other
- Heart Center Duisburg (Evangelical Hospital Niederrhein) - Duisburg
- Amsterdam University Medical Center - Amsterdam
- University Medical Center Utrecht - Utrecht
- Zan Mitrev Clinic - Skopje
- University Hospital of Wales - Cardiff
- Golden Jubilee University National Hospital - Glasgow
- Barts Heart Centre - London
Maryland
- Johns Hopkins University - Baltimore
Michigan
- Helen DeVos Children's Hospital - Grand Rapids
New York
- Mount Sinai Fuster Heart Hospital - New York
South Holland
- Leiden University Medical Center (LUMC) - Leiden
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2023-01-01 |
| Est. Completion | 2027-12-31 |
What NCT06932081 shows while recruiting
NCT06932081 is an observational study that tracks outcomes without assigning an intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 468-participant average among 63 other Congenital Heart Disease trials with a reported enrollment target (15% lower).
The record links to 8 conditions, with Congenital Heart Disease appearing as the primary indexed condition, and to 1 intervention - of which SGLT2 inhibitors is the first listed.
NCT06932081 lists 11 locations in 5 states (Other, Maryland, Michigan).
Frequently Asked Questions
What is clinical trial NCT06932081 about?
NCT06932081 is a clinical study titled "Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry". This real-world, international registry aims to evaluate the current experience with sodium-glucose cotransporter 2 inhibitors (SGLT2i) in adult congenital heart disease (ACHD) patients by investigating the prescription patterns, safety, tolerability, and potential beneficial effects on heart failur...
What is the current status of trial NCT06932081?
This trial is currently recruiting. The enrollment target is 400 participants. The study started on 2023-01-01. Estimated completion is 2027-12-31.
What conditions does trial NCT06932081 study?
This clinical trial studies the following conditions: Congenital Heart Disease, Single-ventricle, Adult Congenital Heart Disease, Tetralogy of Fallot (TOF), Fontan.
What interventions are being tested in trial NCT06932081?
The interventions under investigation include: SGLT2 inhibitors (DRUG).
Who is sponsoring clinical trial NCT06932081?
This trial is sponsored by Leiden University Medical Center, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06932081 being conducted?
This trial has 11 study locations across Maryland, Michigan, New York, South Holland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Congenital Heart Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06932081's enrollment target sits among peer trials
400 9th of 63 higher than 55 of 63 other Congenital Heart Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Congenital Heart Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Fontan Fitness Trial
RECRUITING · NA
-
Fontan Associated Liver Disease and the Evaluation of Biomarkers for Disease Severity Assessment
RECRUITING
-
A Study of Invasive Hemodynamic for MACHD Registry
RECRUITING
-
Remote Monitoring in Pregnant Women With Congenital Heart Disease Using Wrist Wearables
RECRUITING
-
Fetal Electrophysiologic Abnormalities in High-Risk Pregnancies Associated With Fetal Demise
RECRUITING
-
PDA for Kidneys Study
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI